The company behind an imaging agent meant to identify prostate cancer said it received FDA approval on Thursday for use in patients with suspected metastasis or recurrence. Lantheus Holdings, Inc. said its PYLARIFY injection will now be immediately available in parts of the mid-Atlantic and southern regions, with availability expected to rapidly expand over the next six months.
Lantheus Gets FDA OK of Pylarify Imag... - Advanced Prostate...
Lantheus Gets FDA OK of Pylarify Imaging Agent for Prostate Cancer
Written by
Max225
To view profiles and participate in discussions please or .
Read more about...
Not what you're looking for?
You may also like...
FDA Approves another PSMA PET scan for Prostate Cancer Imaging
https://www.onclive.com/view/fda-approves-tlx591-cdx-for-prostate-cancer-imaging
Like the other two...
\"Bombesin - A New Frontier for Prostate Cancer Imaging\"
They are studying the imaging of prostate cancer with Ga 68 gastrin-releasing peptide receptor...
Rice University professor waits on FDA to approve what she hopes will be a cure for prostate cancer
were cancer-free. Now, as they wait for the FDA's approval, Halas explained why this achievement...
FDA Approves Darolutamide Plus Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer
Other triple therapy approved by the FDA. The article has the basic results of the ARASENS trial.
My dad has stage 4 prostate cancer
My dad has stage 4 prostate cancer the doctor said he has 3 months to live and it has spread to the...
Prostate cancer and other cancers
metastatic prostate cancer 
Useful Prostate Cancer books
Friend with advanced Prostate cancer
FDA Grants Fast Track Designation for 177Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer
